The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation
The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation
复制标题
DOI：
10.1016/j.transproceed.2007.09.015
复制
发表时间：
2007-11-01
影响因子：
0.9
通讯作者：
Gorski, A.
中科院分区：
文献类型：
--
作者：
Korczak-Kowalska, G.;Wierzbicki, P.;Gorski, A.
越来越多的研究表明，CD 4（+）CD 25（+）T调节细胞（Treg）在下调对同种异体抗原的免疫应答中发挥重要作用。在这项研究中，我们研究了免疫抑制治疗，包括环孢素（CsA）或雷帕霉素（西罗莫司），对肾移植受者外周血中CD 4（+）CD 25（+），CD 4（+）CD 25（+）FOXP 3（+）和CD 4（+）CD 25（+）CTLA-4（+）T细胞水平的可能影响。这项研究是在肾移植受者中进行的，这些受者表现出平稳的稳定病程（RAR-S; n = 15）与活检证实的慢性排斥反应（RAR-CH; n = 12）。根据免疫抑制方案将患者分为：组1（泼尼松+CsA+Aza）和组II（泼尼松+西罗莫司）。对照组为10名健康献血员。我们检测了外周血T细胞中CD 4、CD 25、CTLA-4和Foxp 3的表达。用FACSCalibur（BD Biosciences）仪器进行流式细胞术，使用Cell Quest软件分析数据。雷帕霉素（西罗莫司）治疗患者中CD 4（+）CD 25（+）Foxp 3（+）T细胞的百分比与健康个体中观察到的没有差异，但与CsA治疗患者相比显着较高。与接受雷帕霉素治疗的患者或健康供体相比，CsA治疗导致两组（RAR-S和RAR-CH）肾移植后CD 4（+）CD 25（+）CTLA-4（+）和CD 4（+）CD 25（+）Foxp 3（+）调节性T细胞百分比降低。免疫抑制治疗的类型（有或没有
A growing number of studies suggest that CD4(+)CD25(+) T regulatory (Treg) cells play a significant role to downregulate the immune response to alloantigens. In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. The study was performed on renal allograft recipients who displayed uneventful stable courses (RAR-S; n = 15) versus biopsy-proven chronic rejection (RAR-CH; n = 12). The patients were divided based on the immunosuppressive protocol: group 1 (prednisone+CsA+Aza) and group II (prednisone+sirolimus). The control group consisted of 10 healthy blood donors. We examined the expression of CD4, CD25, CTLA-4, and Foxp3 in peripheral blood T cells. Flow cytometry was performed with a FACSCalibur (BD Biosciences) instrument with data analyzed using Cell Quest software. The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients. CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors. The type of immunosuppressive therapy (with or without